The global impact of the COVID-19 pandemic on the management and course of chronic urticaria

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Kocatürk, Emek
• dc.contributor.author Giménez Arnau, Anna Maria
• dc.contributor.author Maurer, Marcus
• dc.date.accessioned 2021-05-18T07:00:12Z
• dc.date.available 2021-05-18T07:00:12Z
• dc.date.issued 2021
• dc.description.abstract Introduction: The COVID-19 pandemic dramatically disrupts health care around the globe. The impact of the pandemic on chronic urticaria (CU) and its management are largely unknown. Aim: To understand how CU patients are affected by the COVID-19 pandemic; how specialists alter CU patient management; and the course of CU in patients with COVID-19. Materials and methods: Our cross-sectional, international, questionnaire-based, multicenter UCARE COVID-CU study assessed the impact of the pandemic on patient consultations, remote treatment, changes in medications, and clinical consequences. Results: The COVID-19 pandemic severely impairs CU patient care, with less than 50% of the weekly numbers of patients treated as compared to before the pandemic. Reduced patient referrals and clinic hours were the major reasons. Almost half of responding UCARE physicians were involved in COVID-19 patient care, which negatively impacted on the care of urticaria patients. The rate of face-to-face consultations decreased by 62%, from 90% to less than half, whereas the rate of remote consultations increased by more than 600%, from one in 10 to more than two thirds. Cyclosporine and systemic corticosteroids, but not antihistamines or omalizumab, are used less during the pandemic. CU does not affect the course of COVID-19, but COVID-19 results in CU exacerbation in one of three patients, with higher rates in patients with severe COVID-19. Conclusions: The COVID-19 pandemic brings major changes and challenges for CU patients and their physicians. The long-term consequences of these changes, especially the increased use of remote consultations, require careful evaluation.
• dc.format.mimetype application/pdf
• dc.identifier.citation Kocatürk E, Salman A, Cherrez-Ojeda I, Criado PR, Peter J, Comert-Ozer E, et al. The global impact of the COVID-19 pandemic on the management and course of chronic urticaria. Allergy. 2021 Mar; 76(3): 816-30. DOI: 10.1111/all.14687
• dc.identifier.doi http://dx.doi.org/10.1111/all.14687
• dc.identifier.issn 0105-4538
• dc.identifier.uri http://hdl.handle.net/10230/47573
• dc.language.iso eng
• dc.publisher Wiley-Blackwell
• dc.rights © 2020 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License http://creativecommons.org/licenses/by-nc/4.0/, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by-nc/4.0/
• dc.subject.keyword COVID-19
• dc.subject.keyword SARS-CoV-2
• dc.subject.keyword UCARE
• dc.subject.keyword Chronic urticaria
• dc.subject.keyword Cyclosporine
• dc.subject.keyword Omalizumab
• dc.subject.keyword Pandemic
• dc.subject.keyword Treatment
• dc.title The global impact of the COVID-19 pandemic on the management and course of chronic urticaria
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion